Pharmacotherapy in Ventricular Arrhythmias
Background
Ventricular ectopy is observed in most of the population ranging from isolated premature ventricular contractions to rapid hemodynamically unstable ventricular tachyarrhythmias like ventricular tachycardia and ventricular fibrillation. Multiple mechanisms exist for ventricular arrhythmias such as triggered activity, reentry, and automaticity. Scar-based reentry forms the basis of most malignant VA that can lead to sudden cardiac death.
Many antiarrhythmic drugs have been utilized for the suppression of ventricular arrhythmia. They are commonly classified using the Vaughan-Williams-Singh classification which distinguishes them based on the predominant action on different phases of the cardiac action potential. Class Ic agents are widely used in premature ventricular contraction suppression but are contraindicated in patients with prior myocardial infarction or ischemic scar, and heart failure. Beta-blockers continue to be a mainstay in the treatment of most symptomatic VA and are well tolerated, relatively safe, and have additional benefits in symptomatic coronary heart disease and left ventricular systolic dysfunction. Amiodarone continues to be used for the management of most cases of serious VA especially in the acute setting when accompanied by hemodynamic perturbations but has the disadvantage of having a poor toxicity profile for long-term use
Summary
Historically used for long-term ventricular arrhythmia suppression and prevention of sudden cardiac death,...
Source: Cardiology - Category: Cardiology Source Type: research
More News: Amiodarone | Arrhythmia | Beta-Blockers | Cancer & Oncology | Cardiology | Coronary Heart Disease | Heart | Heart Attack | Heart Disease | Heart Failure | Heart Transplant | Toxicology | Ventricular Arrhythmia | Ventricular Tachycardia